Hormone · Research Phase
Mod GRF 1-29 (CJC-1295 no DAC)
No lawful US pathway
01 · Overview
Modified GRF 1-29 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions, the same tetrasubstituted GRF(1-29) backbone used in CJC-1295 (PMID 15817669). These substitutions are intended to improve resistance to enzymatic breakdown compared with native GRF(1-29).
Unlike CJC-1295 with DAC, it lacks the albumin-binding group that extends half-life (PMID 15817669).
02 · Research summary & key findings
No peer-reviewed clinical trials of the non-DAC form were found; human data exist only for the related long-acting CJC-1295 with DAC, which raised GH and IGF-1 for days in healthy adults (PMID 16352683). Modified GRF 1-29 has been identified in seized doping material, sometimes as unapproved glycine-modified variants (PMID 30136411). GHRH and its synthetic analogs are prohibited by the World Anti-Doping Agency (PMID 34665524), and peptides used in bodybuilding are often mislabeled or contaminated, with poorly defined long-term risks (PMID 41880199).
03 · Regulatory status
Mod GRF 1-29 (CJC-1295 no DAC) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Mod GRF 1-29 (CJC-1295 no DAC) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Hormone
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Mod GRF 1-29 (CJC-1295 no DAC) is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology, 2005. PMID 15817669
- [2]Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab, 2006. PMID 16352683
- [3]Glycine-modified growth hormone secretagogues identified in seized doping material Drug Test Anal, 2019. PMID 30136411
- [4]Advances in the detection of growth hormone releasing hormone synthetic analogs Drug Test Anal, 2021. PMID 34665524
- [5]A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review J Sports Med Phys Fitness, 2026. PMID 41880199
Primary literature
- PubMed: "Mod GRF 1-29"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Mod GRF 1-29"
Registered interventional and observational studies, including status and phase.
- PubChem: "Mod GRF 1-29"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.